In an ongoing trend that has been apparent for several years, the Federal Trade Commission (FTC) is ramping up enforcement of antitrust laws in the health care and private equity domains. Led by Chairperson Lina Khan, the FTC has shown a clear intent to prevent “roll-up” acquisitions by major firms in these sectors.
Recently, the FTC’s mission to curtail these acquisitions gained further traction with their lawsuit against U.S Anesthesia Partners, Inc. (USAP) and its investing private equity firm Welsh, Carlson, Anderson & Stowe (Welsh Carlson). The case, which has been filed in the Southern District of Texas, is seen as a move by the FTC to put action behind their words and intensify enforcement. For more details, please see: Reed Smith’s analysis on JDSupra.
Overall, the lawsuit is poised to serve as a wake-up call for corporations and private equity firms in the health care industry. Lawyers and legal teams within these institutions need to pay close attention to this and similar future FTC actions. A thorough understanding of these developments can help organizations review and plan their acquisition strategies more effectively.
Moreover, the lawsuit against USAP and Welsh Carlson might potentially serve as a benchmark for future FTC cases challenging “roll-up” acquisitions. Legal professionals must keep abreast of these developments and adapt their legal strategies for clients accordingly.